Welcome to our dedicated page for Immatics N.V. SEC filings (Ticker: IMTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immatics N.V. filings document a foreign private issuer whose regulatory record centers on clinical-stage oncology development, financing capacity and public-company governance. Form 6-K reports furnish press releases, interim reports and investor presentations covering PRAME cell therapy and TCR bispecific programs, including anzu-cel, IMA203CD8, IMA402 and IMA401 MAGEA4/8, along with financial results and business updates.
The filings also include incorporation-by-reference language for Form S-8 and Form F-3 registration statements, leadership and governance disclosures, forward-looking clinical and regulatory risk statements, and capital-structure or shareholder matters tied to the company's Nasdaq-traded security.
Immatics N.V. (IMTX) reported that officer James Nelson, General Counsel and Corporate Secretary, received equity-based compensation on August 14, 2026. He was granted a stock option for 181,200 ordinary shares at an exercise price of $9.44 per share, expiring on August 13, 2036, vesting 25% on August 14, 2027 and then in 12 equal quarterly installments over three years. He also received 43,800 restricted stock units, each representing one ordinary share, vesting in four equal annual installments on each anniversary of August 14, 2027. Following these grants, his reported holdings in these derivative awards are 181,200 option-linked shares and 43,800 RSU-linked shares, all held directly.
Immatics N.V. reported collaboration revenue of €9.1 million for Q2 2026 and €16.8 million for the first half of 2026, compared with €4.7 million and €23.3 million in the prior-year periods, driven by timing and cost-based recognition under its Moderna and BMS partnerships. Research and development expenses rose to €62.4 million in Q2 and €121.6 million for the first half, reflecting intensified clinical activity, especially the Phase 3 SUPRAME trial of PRAME cell therapy anzu-cel in melanoma and related programs. General and administrative expenses increased moderately to €28.5 million for the half, as the company builds commercial capabilities.
Net loss was €62.5 million in Q2 2026 and €120.3 million for the first half, versus €70.3 million and €110.2 million a year earlier. Financial results improved due to sharply lower foreign-exchange losses, producing a positive financial result of €12.7 million for the half. Cash and cash equivalents were €232.5 million and other financial assets €160.9 million, totaling €393.4 million at June 30, 2026; management states this is sufficient to fund operations for at least 12 months. Immatics also raised €21.6 million gross via its at-the-market equity program and ended the period with €399.6 million in shareholders’ equity while advancing its PRAME franchise and recording a new clinical milestone with Moderna.
Baker Bros. Advisors LP and related reporting persons filed Amendment No. 6 to report their ownership in Immatics N.V. They beneficially own 9,508,565 ordinary shares of Immatics, held directly by Baker Brothers Life Sciences, L.P. and 667, L.P., which may be deemed to be indirectly owned by the reporting persons through management and control arrangements.
This position represents 7.0% of Immatics’ ordinary shares, based on 136,673,161 shares outstanding as of March 31, 2026, as cited from Immatics’ Form 6-K. The reporting persons have sole voting and dispositive power over all 9,508,565 shares and no shared voting or dispositive power.
Immatics N.V. reported the initial insider status of Pepin James Nelson, who serves as General Counsel and Corporate Secretary. The Form 3 data lists no equity transactions and shows no reported derivative positions, establishing his role as an officer-reporting person rather than disclosing trading activity.
Immatics N.V. director Adam Leo Stone received a grant of stock options representing 48,000 Ordinary Shares. The options carry an exercise price of $9.09 per share and expire on June 15, 2036. According to the terms, these options vest 100% on the first anniversary of the grant date, on June 16, 2026. Following this grant, Stone holds 48,000 stock options directly as a compensation-related award rather than an open-market purchase.
Immatics N.V. director Alise Reicin reported a compensation-related award of stock options. She received 48,000 Stock Options (Right to Buy) to acquire Immatics ordinary shares.
The options carry an exercise price of $9.09 per share, expire on June 15, 2036, and vest 100% on June 16, 2026. Following this grant, Reicin holds 48,000 derivative securities of this type directly.
Immatics N.V. director Michael G. Atieh received a grant of stock options covering 48,000 underlying ordinary shares. The options have an exercise price of $9.09 per share, expire on June 15, 2036, and vest 100% on the first anniversary of the June 16, 2025 grant date.
Immatics N.V. director Carter Paul Rutherford received a grant of stock options covering 48,000 Ordinary Shares. The options have an exercise price of $9.09 per share and expire on June 15, 2036. According to the footnote, the options vest 100% on the first anniversary of the grant date, June 16, 2026. This is a compensation-related award, not an open-market share purchase or sale.
Immatics N.V. director Eliot Forster received a grant of stock options covering 48,000 ordinary shares. The options have an exercise price of $9.09 per share and expire on June 15, 2036. They vest 100% on the first anniversary of the grant date, June 16, 2026, and result in total option holdings of 48,000 derivative securities reported in this filing.
Immatics N.V. director Peter Alan Chambre received a grant of stock options as part of his compensation. He was awarded 48,000 Stock Options (Right to Buy), each allowing purchase of one ordinary share at an exercise price of $9.09 per share.
The options vest 100% on the first anniversary of the grant date, June 16, 2026, and expire on June 15, 2036. Following this award, his reported holdings in this option grant total 48,000 derivative securities, with no shares bought or sold in the market in this filing.